Avidity Biosciences price target raised to $35 from $33 at Credit Suisse

Credit Suisse analyst Judah Frommer raised the firm’s price target on Avidity Biosciences to $35 from $33 and keeps an Outperform rating on the shares. The analyst said the company provided a "largely positive" interim update of the MARINA Phase 1/2 trial that appears to confirm ‘1001’s activity in the nucleus. Frommer added that splicing changes are a step forward as a key biomarker and that the data underscore the potential of the platform.